Detalhe da pesquisa
1.
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Lancet
; 403(10432): 1164-1175, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402887
2.
Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Lancet Infect Dis
; 23(5): 609-620, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36638819
3.
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Lancet Infect Dis
; 21(6): 834-846, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33516293